Rapid oral desensitization to anti-tuberculosis drugs Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities Year: 2010
Cisplatin and docetaxel induction chemotherapy results Source: Eur Respir J 2005; 26: Suppl. 49, 77s Year: 2005
Pegylated liposomal doxorubicin HCl (Caelyx) in combination with sandostatin LAR as salvage therapy in patients with small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 78s Year: 2005
Oral combination therapy bosentan/sildenafil delays time to clinical worsening in comparison to bosentan monotherapy Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008
Evaluation of the efficacy of cisplatin–etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in LCNEC Source: ERJ Open Res, 3 (1) 00128-2016; 10.1183/23120541.00128-2016 Year: 2017
A randomised phase III trial by the European lung cancer working party comparing sequential administration of cisplatin-based chemotherapy followed by a taxan and a cisplatin-based standard chemotherapy, with the use of taxan as salvage treatment Source: Eur Respir J 2006; 28: Suppl. 50, 833s Year: 2006
Pulmonary toxicity during chemotherapy with etopiside and carboplatin Source: Eur Respir J 2003; 22: Suppl. 45, 64s Year: 2003
Surgery following neoadjuvant therapy is safe and offers improved long-term prognosis Source: Annual Congress 2007 - Controversies in surgical oncology Year: 2007
Short-term efficacy of advanced NSCLC patients receiving anlotinib hydrochloride as the first and second-line treatment Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020
Paradoxical response to adequate antituberculosis treatment Source: Eur Respir J 2004; 24: Suppl. 48, 724s Year: 2004
Optimisation of chemotherapy in the era of immunotherapy Source: Eur Respir J, 52 (4) 1801698; 10.1183/13993003.01698-2018 Year: 2018
Pegylated liposomal doxorubicin compared with traditional doxorubicin in combination chemo-radiotherapy for small cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 465s Year: 2002
Concurrent chemoradiotherapy with carboplatin and paclitaxel followed by consolidation chemotherapy with vinorelbine for locally advanced inoperable nonsmall-cell lung cancer: A multiinstitutional phase II study Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010
Efficacy of induction chemotherapy and following simultaneous radiochemotherapy versus induction chemotherapy and radiotherapy alone in inoperable NSCLC (Stage IIIA/IIIB): update of CT/RT 99/97 Source: Annual Congress 2004 - Management of lung cancer and innovative therapies Year: 2004
Combination therapy with sotatercept analog RAP-011 is superior to sildenafil alone in severe experimental PAH and RAP-011 benefits persist after treatment cessation Source: Virtual Congress 2020 – Updated assessment and treatment of pulmonary arterial hypertension Year: 2020
Combination therapy in severe pulmonary hypertension with bosentan and treprostinil: successful switch from subcutaneous to intravenous application Source: Eur Respir J 2006; 28: Suppl. 50, 384s Year: 2006
Cisplatin/vinorelbine remains a valid option for the front-line chemotherapy of NSCLC Source: Eur Respir J 2004; 24: Suppl. 48, 302s Year: 2004